3D Medicines Inc. (HKG:1244)

Hong Kong · Delayed Price · Currency is HKD

2.470

+0.210 (9.29%)

Sep 18, 2026, 4:08 PM HKT

Market Cap	607.42M -68.4%
Revenue (ttm)	412.66M -20.3%
Net Income	-200.20M
EPS	-0.81
Shares Out	245.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,500
Open	2.330
Previous Close	2.260
Day's Range	2.300 - 2.470
52-Week Range	1.820 - 8.380
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About 3D Medicines

3D Medicines Inc., a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products in the People’s Republic of China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC, and TMB-H advanced cancer; and in Phase II clinical trial... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Employees 162

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 1244

Full Company Profile

Financial Performance

In 2025, 3D Medicines's revenue was 356.09 million, a decrease of -20.10% compared to the previous year's 445.65 million. Losses were -177.53 million, -2.81% less than in 2024.

Financial numbers in CNY Financial Statements